Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» donanemab
donanemab
Eli Lilly Alzheimer's drug approved by US FDA
Reuters
Tue, 07/2/24 - 03:09 pm
Eli Lilly
donanemab
Alzheimer's disease
FDA
Kisunla
5 FDA Decisions to Watch in the Second Half of 2024
BioSpace
Mon, 06/24/24 - 11:29 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Adaptimmune
afami-cel
advanced synovial sarcoma
Lykos Therapeutics
MDMA
PTSD
Bristol Myers Squibb
KarXT
schizophrenia
Daiichi Sankyo
AstraZeneca
Dato-DXd
non-small cell lung cancer
What Would a Donanemab Approval Mean for Leqembi?
BioSpace
Mon, 06/24/24 - 10:47 am
Eli Lilly
donanemab
Biogen
Eisai
Leqembi
FDA
Alzheimer's disease
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
Motley Fool
Sun, 06/16/24 - 08:54 pm
Eli Lilly
Alzheimer's disease
donanemab
Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now
Pharma Voice
Thu, 06/13/24 - 10:50 am
Eli Lilly
Alzheimer's disease
donanemab
amyloid
tau
Lilly Alzheimer’s drug gets unanimous backing of FDA panel
BioPharma Dive
Mon, 06/10/24 - 06:09 pm
Eli Lilly
FDA
donanemab
Alzheimer's disease
FDA staff raise no major concerns about Eli Lilly Alzheimer's drug
Reuters
Thu, 06/6/24 - 09:11 pm
Eli Lilly
FDA
Alzheimer's disease
donanemab
FDA lays out donanemab concerns ahead of meeting, as Lilly vigorously defends safety
Fierce Biotech
Thu, 06/6/24 - 11:45 am
Eli Lilly
donanemab
FDA
Alzheimer's disease
Lilly gets a date with FDA to discuss Alzheimer's med donanemab
Fierce Biotech
Tue, 05/7/24 - 11:21 am
Eli Lilly
FDA
advisory committees
Alzheimer's disease
donanemab
Eli Lilly Gears Up for Donanemab Adcomm as FDA Ponders Changes to Format
BioSpace
Mon, 05/6/24 - 11:43 am
Eli Lilly
FDA
donanemab
advisory committees
Alzheimer's disease
Lilly Alzheimer's med glides out of Leqembi's slipstream with FDA adcomm request
Fierce Biotech
Wed, 04/17/24 - 09:58 pm
Eli Lilly
donanemab
Alzheimer's disease
Leqembi
Biogen
Eisai
FDA
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
Fierce Biotech
Tue, 03/12/24 - 11:34 am
Biogen
Eisai
Aduhelm
FDA
Alzheimer's disease
amyloid
Eli Lilly
donanemab
Setbacks reset views on highly touted Alzheimer's and ALS drugs
Axios
Mon, 03/11/24 - 05:06 pm
Alzheimer's disease
ALS
Amylyx
Relyvrio
Eli Lilly
donanemab
Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm
BioSpace
Fri, 03/8/24 - 11:55 am
Eli Lilly
FDA
Alzheimer's disease
donanemab
Where’s Lilly’s Alzheimer’s approval?
Stat
Tue, 03/5/24 - 11:08 am
Eli Lilly
donanemab
Alzheimer's disease
Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.
Motley Fool
Fri, 11/10/23 - 12:19 pm
Eli Lilly
donanemab
tirzepatide
mirikizumab
lebrikizumab
pirtobrutinib
As 'harvest time' arrives for Alzheimer's, neuroscientist reflects on next steps for drug development
Fierce Biotech
Mon, 10/16/23 - 10:12 am
Alzheimer's disease
Biogen
Eisai
Eli Lilly
Leqembi
donanemab
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Mon, 09/11/23 - 12:34 pm
Alzheimer's disease
Eli Lilly
Biogen
Eisai
Leqembi
donanemab
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Wed, 07/19/23 - 10:27 am
Eli Lilly
donanemab
Eisai
Biogen
Leqembi
Alzheimer's disease
Pages
1
2
3
next ›
last »